NR4A1 and breast carcinoma: The mTOR inhibitor everolimus is a systemic treatment option for hormone receptor-positive HER2 receptor-negative advanced breast cancer when co-administered with exemestane, in addition to renal cell carcinoma and pancreatic neuroendocrine tumours [94].